PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28659037-0	2017	Myrcene, an Aromatic Volatile Compound, Ameliorates Human Skin Extrinsic Aging via Regulation of MMPs Production.	myrcene	0-7	matrix metallopeptidase 1	Homo sapiens	97-101
1864266-13	1991	The possibility that myrcene exerts its antimutagenic activity by inhibiting certain forms of the cytochrome P-450 isoenzymes required for activation of premutagens and precarcinogenes is discussed.	myrcene	21-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
32735520-7	2021	OBJECTIVE: This study aimed to (i) characterize the physico-chemical properties and release behavior of myrcene encapsulated in the four different shell matrices of alpha-CD, beta-CD, gamma-CD and 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD), which were selected from the perspective of stability, and (ii) determine the release mechanism of myrcene in inclusion complexes (ICs).	myrcene	104-111	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	165-173
32735520-7	2021	OBJECTIVE: This study aimed to (i) characterize the physico-chemical properties and release behavior of myrcene encapsulated in the four different shell matrices of alpha-CD, beta-CD, gamma-CD and 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD), which were selected from the perspective of stability, and (ii) determine the release mechanism of myrcene in inclusion complexes (ICs).	myrcene	104-111	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	175-182
32735520-7	2021	OBJECTIVE: This study aimed to (i) characterize the physico-chemical properties and release behavior of myrcene encapsulated in the four different shell matrices of alpha-CD, beta-CD, gamma-CD and 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD), which were selected from the perspective of stability, and (ii) determine the release mechanism of myrcene in inclusion complexes (ICs).	myrcene	104-111	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	235-242
32735520-15	2021	Thirdly, the calculated binding energies of the optimized structures for alpha-CD/myrcene, beta-CD/myrcene, gamma-CD/myrcene, and HP-beta-CD/myrcene ICs were -4.28, -3.82, -4.04, and -3.72 kcal/mol, respectively.	myrcene	82-89	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	133-140
32735520-15	2021	Thirdly, the calculated binding energies of the optimized structures for alpha-CD/myrcene, beta-CD/myrcene, gamma-CD/myrcene, and HP-beta-CD/myrcene ICs were -4.28, -3.82, -4.04, and -3.72 kcal/mol, respectively.	myrcene	99-106	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	91-98
32735520-15	2021	Thirdly, the calculated binding energies of the optimized structures for alpha-CD/myrcene, beta-CD/myrcene, gamma-CD/myrcene, and HP-beta-CD/myrcene ICs were -4.28, -3.82, -4.04, and -3.72 kcal/mol, respectively.	myrcene	99-106	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	133-140
32735520-15	2021	Thirdly, the calculated binding energies of the optimized structures for alpha-CD/myrcene, beta-CD/myrcene, gamma-CD/myrcene, and HP-beta-CD/myrcene ICs were -4.28, -3.82, -4.04, and -3.72 kcal/mol, respectively.	myrcene	99-106	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	91-98
32735520-15	2021	Thirdly, the calculated binding energies of the optimized structures for alpha-CD/myrcene, beta-CD/myrcene, gamma-CD/myrcene, and HP-beta-CD/myrcene ICs were -4.28, -3.82, -4.04, and -3.72 kcal/mol, respectively.	myrcene	99-106	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	133-140
32735520-15	2021	Thirdly, the calculated binding energies of the optimized structures for alpha-CD/myrcene, beta-CD/myrcene, gamma-CD/myrcene, and HP-beta-CD/myrcene ICs were -4.28, -3.82, -4.04, and -3.72 kcal/mol, respectively.	myrcene	99-106	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	91-98
32735520-15	2021	Thirdly, the calculated binding energies of the optimized structures for alpha-CD/myrcene, beta-CD/myrcene, gamma-CD/myrcene, and HP-beta-CD/myrcene ICs were -4.28, -3.82, -4.04, and -3.72 kcal/mol, respectively.	myrcene	99-106	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	133-140
32735520-16	2021	Finally, the encapsulation of myrcene with alpha-CD and beta-CD was preferable according to the stability and release characteristics.	myrcene	30-37	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	43-51
32735520-16	2021	Finally, the encapsulation of myrcene with alpha-CD and beta-CD was preferable according to the stability and release characteristics.	myrcene	30-37	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	56-63
32962470-7	2020	Moreover, the protective effect of MC was evidenced with reduced leukocyte infiltration in BALF, hypersensitive specific IgE levels with a profound decrease in the inflammatory cytokines such as IL-2, IL-4, IL-18, and IL-21 in MC administered animals compared to the asthma-induced group.	myrcene	35-37	interleukin 2	Rattus norvegicus	195-199
32962470-7	2020	Moreover, the protective effect of MC was evidenced with reduced leukocyte infiltration in BALF, hypersensitive specific IgE levels with a profound decrease in the inflammatory cytokines such as IL-2, IL-4, IL-18, and IL-21 in MC administered animals compared to the asthma-induced group.	myrcene	35-37	interleukin 4	Rattus norvegicus	201-205
32962470-7	2020	Moreover, the protective effect of MC was evidenced with reduced leukocyte infiltration in BALF, hypersensitive specific IgE levels with a profound decrease in the inflammatory cytokines such as IL-2, IL-4, IL-18, and IL-21 in MC administered animals compared to the asthma-induced group.	myrcene	35-37	interleukin 18	Rattus norvegicus	207-212
32962470-7	2020	Moreover, the protective effect of MC was evidenced with reduced leukocyte infiltration in BALF, hypersensitive specific IgE levels with a profound decrease in the inflammatory cytokines such as IL-2, IL-4, IL-18, and IL-21 in MC administered animals compared to the asthma-induced group.	myrcene	35-37	interleukin 21	Rattus norvegicus	218-223
31446830-3	2019	Since plant-derived mixtures of cannabinoids and the Cannabis component myrcene have been suggested as pain therapeutics, we screened terpenes found in Cannabis for activity at TRPV1.	myrcene	72-79	transient receptor potential cation channel subfamily V member 1	Homo sapiens	177-182
31446830-6	2019	Myrcene dominates the TRPV1-mediated calcium responses seen with terpenoid mixtures.	myrcene	0-7	transient receptor potential cation channel subfamily V member 1	Homo sapiens	22-27
31446830-7	2019	Myrcene-induced calcium influx is inhibited by the TRPV1 inhibitor capsazepine and Myrcene elicits TRPV1 currents in the whole-cell patch-clamp configuration.	myrcene	0-7	transient receptor potential cation channel subfamily V member 1	Homo sapiens	51-56
31446830-7	2019	Myrcene-induced calcium influx is inhibited by the TRPV1 inhibitor capsazepine and Myrcene elicits TRPV1 currents in the whole-cell patch-clamp configuration.	myrcene	0-7	transient receptor potential cation channel subfamily V member 1	Homo sapiens	99-104
31446830-7	2019	Myrcene-induced calcium influx is inhibited by the TRPV1 inhibitor capsazepine and Myrcene elicits TRPV1 currents in the whole-cell patch-clamp configuration.	myrcene	83-90	transient receptor potential cation channel subfamily V member 1	Homo sapiens	99-104
31446830-10	2019	Myrcene pre-application and residency at TRPV1 appears to negatively impact subsequent responses to TRPV1 ligands such as Cannabidiol, indicating allosteric modulation and possible competition by Myrcene.	myrcene	0-7	transient receptor potential cation channel subfamily V member 1	Homo sapiens	41-46
31446830-10	2019	Myrcene pre-application and residency at TRPV1 appears to negatively impact subsequent responses to TRPV1 ligands such as Cannabidiol, indicating allosteric modulation and possible competition by Myrcene.	myrcene	0-7	transient receptor potential cation channel subfamily V member 1	Homo sapiens	100-105
31446830-10	2019	Myrcene pre-application and residency at TRPV1 appears to negatively impact subsequent responses to TRPV1 ligands such as Cannabidiol, indicating allosteric modulation and possible competition by Myrcene.	myrcene	196-203	transient receptor potential cation channel subfamily V member 1	Homo sapiens	100-105
31446830-11	2019	Molecular docking studies suggest a non-covalent interaction site for Myrcene in TRPV1 and identifies key residues that form partially overlapping Myrcene and Cannabidiol binding sites.	myrcene	70-77	transient receptor potential cation channel subfamily V member 1	Homo sapiens	81-86
31446830-11	2019	Molecular docking studies suggest a non-covalent interaction site for Myrcene in TRPV1 and identifies key residues that form partially overlapping Myrcene and Cannabidiol binding sites.	myrcene	147-154	transient receptor potential cation channel subfamily V member 1	Homo sapiens	81-86
31446830-13	2019	These data establish TRPV1 as a target of Myrcene and suggest the therapeutic potential of analgesic formulations containing Myrcene.	myrcene	42-49	transient receptor potential cation channel subfamily V member 1	Homo sapiens	21-26
3377821-1	1988	We have investigated the ability of camphor, menthol, pinene, limonene and myrcene to induce in rats members of a cytochrome P-450 sub-family termed PB P-450.	myrcene	75-82	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	114-130
33007969-7	2020	Myrcene treatment resulted in significant downregulation of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) compared to untreated ADX rats.	myrcene	0-7	interleukin 1 alpha	Rattus norvegicus	88-96
33007969-7	2020	Myrcene treatment resulted in significant downregulation of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) compared to untreated ADX rats.	myrcene	0-7	interleukin 6	Rattus norvegicus	98-102
33007969-7	2020	Myrcene treatment resulted in significant downregulation of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) compared to untreated ADX rats.	myrcene	0-7	tumor necrosis factor	Rattus norvegicus	108-117
33007969-8	2020	In addition, myrcene resulted in significant downregulation of immunomodulatory factors (IFNgamma and NF-kappaB) and anti-inflammatory markers (IL-4 and IL-10) in treated ADX compared to untreated ADX.	myrcene	13-20	interleukin 18	Rattus norvegicus	89-97
33007969-8	2020	In addition, myrcene resulted in significant downregulation of immunomodulatory factors (IFNgamma and NF-kappaB) and anti-inflammatory markers (IL-4 and IL-10) in treated ADX compared to untreated ADX.	myrcene	13-20	interleukin 4	Rattus norvegicus	144-148
33007969-8	2020	In addition, myrcene resulted in significant downregulation of immunomodulatory factors (IFNgamma and NF-kappaB) and anti-inflammatory markers (IL-4 and IL-10) in treated ADX compared to untreated ADX.	myrcene	13-20	interleukin 10	Rattus norvegicus	153-158
33007969-9	2020	Myrcene significantly increased the antioxidant molecules (CAT, GSH, and SOD) and decreased MDA levels in treated ADX compared to untreated.	myrcene	0-7	catalase	Rattus norvegicus	59-62
33007969-10	2020	Moreover, myrcene treatment reduced the expression of COX-2, iNOS, KIM-1, and kidney functional molecules (UREA, LDH, total protein, and creatinine) in ADX treated compared to ADX untreated.	myrcene	10-17	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	54-59
33007969-10	2020	Moreover, myrcene treatment reduced the expression of COX-2, iNOS, KIM-1, and kidney functional molecules (UREA, LDH, total protein, and creatinine) in ADX treated compared to ADX untreated.	myrcene	10-17	nitric oxide synthase 2	Rattus norvegicus	61-65
33007969-10	2020	Moreover, myrcene treatment reduced the expression of COX-2, iNOS, KIM-1, and kidney functional molecules (UREA, LDH, total protein, and creatinine) in ADX treated compared to ADX untreated.	myrcene	10-17	hepatitis A virus cellular receptor 1	Rattus norvegicus	67-72
28659037-5	2017	We showed that myrcene decreased the production of ROS, MMP-1, MMP-3, and IL-6, and increased TGF-[Formula: see text]1 and type I procollagen secretions.	myrcene	15-22	matrix metallopeptidase 1	Homo sapiens	56-61
28659037-5	2017	We showed that myrcene decreased the production of ROS, MMP-1, MMP-3, and IL-6, and increased TGF-[Formula: see text]1 and type I procollagen secretions.	myrcene	15-22	matrix metallopeptidase 3	Homo sapiens	63-68
28659037-5	2017	We showed that myrcene decreased the production of ROS, MMP-1, MMP-3, and IL-6, and increased TGF-[Formula: see text]1 and type I procollagen secretions.	myrcene	15-22	interleukin 6	Homo sapiens	74-78
28659037-5	2017	We showed that myrcene decreased the production of ROS, MMP-1, MMP-3, and IL-6, and increased TGF-[Formula: see text]1 and type I procollagen secretions.	myrcene	15-22	collagen type I alpha 2 chain	Homo sapiens	123-141
28659037-6	2017	Furthermore, myrcene treatment (0.1-10[Formula: see text][Formula: see text]M) dramatically reduced the activation of MAPK-related signaling molecules such as p-ERK, p-p38, and p-JNK and AP-1 including p-c-Jun and p-c-Fos.	myrcene	13-20	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	204-209
28659037-6	2017	Furthermore, myrcene treatment (0.1-10[Formula: see text][Formula: see text]M) dramatically reduced the activation of MAPK-related signaling molecules such as p-ERK, p-p38, and p-JNK and AP-1 including p-c-Jun and p-c-Fos.	myrcene	13-20	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	216-221
25434744-2	2015	Based on this result, the random and block copolymerization of myrcene and isoprene (IP) resulted in novel elastomers that comprise the amorphous iso-3,4-PMY and iso-3,4-PIP sequences.	myrcene	63-70	prolactin induced protein	Homo sapiens	170-173
27543726-0	2016	Enhancement and regulation effect of myrcene on antibody response in immunization with ovalbumin and Ag85B in mice.	myrcene	37-44	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	87-96
27543726-3	2016	OBJECTIVE: This study was performed to investigate the enhancement of antigen-specific immune responses by myrcene, a member of the terpene family with fewer carbon atoms (C10) than pyriproxyfen.	myrcene	107-114	gene rich cluster, C10 gene	Mus musculus	172-175
27543726-9	2016	Myrcene increased OVA-specific IgG2a titer, suggesting induction of Th1-immune response.	myrcene	0-7	immunoglobulin heavy variable V1-9	Mus musculus	31-36
25622554-3	2015	At non-cytotoxic concentrations, myrcene and limonene inhibited IL-1beta-induced nitric oxide production (IC50=37.3mug/ml and 85.3microg/ml, respectively), but E-caryophyllene was inactive.	myrcene	33-40	interleukin 1 beta	Homo sapiens	64-72
25622554-4	2015	Myrcene, and limonene to a lesser extent, also decreased IL-1beta-induced NF-kappaB, JNK and p38 activation and the expression of inflammatory (iNOS) and catabolic (MMP-1 and MMP-13) genes, while increasing the expression of anti-catabolic genes (TIMP-1 and -3 by myrcene and TIMP-1 by limonene).	myrcene	0-7	interleukin 1 beta	Homo sapiens	57-65
25622554-4	2015	Myrcene, and limonene to a lesser extent, also decreased IL-1beta-induced NF-kappaB, JNK and p38 activation and the expression of inflammatory (iNOS) and catabolic (MMP-1 and MMP-13) genes, while increasing the expression of anti-catabolic genes (TIMP-1 and -3 by myrcene and TIMP-1 by limonene).	myrcene	0-7	mitogen-activated protein kinase 1	Homo sapiens	93-96
25622554-4	2015	Myrcene, and limonene to a lesser extent, also decreased IL-1beta-induced NF-kappaB, JNK and p38 activation and the expression of inflammatory (iNOS) and catabolic (MMP-1 and MMP-13) genes, while increasing the expression of anti-catabolic genes (TIMP-1 and -3 by myrcene and TIMP-1 by limonene).	myrcene	0-7	matrix metallopeptidase 13	Homo sapiens	175-181
25622554-4	2015	Myrcene, and limonene to a lesser extent, also decreased IL-1beta-induced NF-kappaB, JNK and p38 activation and the expression of inflammatory (iNOS) and catabolic (MMP-1 and MMP-13) genes, while increasing the expression of anti-catabolic genes (TIMP-1 and -3 by myrcene and TIMP-1 by limonene).	myrcene	0-7	TIMP metallopeptidase inhibitor 1	Homo sapiens	247-260
25622554-4	2015	Myrcene, and limonene to a lesser extent, also decreased IL-1beta-induced NF-kappaB, JNK and p38 activation and the expression of inflammatory (iNOS) and catabolic (MMP-1 and MMP-13) genes, while increasing the expression of anti-catabolic genes (TIMP-1 and -3 by myrcene and TIMP-1 by limonene).	myrcene	0-7	TIMP metallopeptidase inhibitor 1	Homo sapiens	247-253
25622554-4	2015	Myrcene, and limonene to a lesser extent, also decreased IL-1beta-induced NF-kappaB, JNK and p38 activation and the expression of inflammatory (iNOS) and catabolic (MMP-1 and MMP-13) genes, while increasing the expression of anti-catabolic genes (TIMP-1 and -3 by myrcene and TIMP-1 by limonene).	myrcene	264-271	interleukin 1 beta	Homo sapiens	57-65
17046597-6	2006	Microsomes prepared from Sf9 cells co-expressing baculoviral-mediated recombinant CYP9T2 and housefly (Musca domestica) NADPH-cytochrome P450 reductase converted myrcene to ipsdienol.	myrcene	162-169	NADPH--cytochrome P450 reductase	Musca domestica	120-151
21245202-8	2011	In contrast, curcumin, myrcene and cineole significantly increased GSH, CAT, GSH-Px and CuZn-SOD levels but decreased formation of TBARS.	myrcene	23-30	catalase	Rattus norvegicus	72-75
21245202-8	2011	In contrast, curcumin, myrcene and cineole significantly increased GSH, CAT, GSH-Px and CuZn-SOD levels but decreased formation of TBARS.	myrcene	23-30	superoxide dismutase 1	Rattus norvegicus	88-96
19034575-8	2008	Microsomes, prepared from Sf9 cells co-expressing baculoviral-mediated recombinant IcCYP9T1 and house fly (Musca domestica) NADPH-cytochrome P450 reductase, converted myrcene to ~85%-(R)-(-)-ipsdienol.	myrcene	167-174	NADPH--cytochrome P450 reductase	Musca domestica	124-155
15299125-11	2004	At3g25810 TPS catalyzes the formation of a set of monoterpenes that is very similar to those produced by AtTPS-Cin, but its major products are myrcene and (E)-beta-ocimene, and it does not form 1,8-cineole.	myrcene	143-150	terpene synthase-like sequence-1,8-cineole	Arabidopsis thaliana	105-114